IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Phone207-556-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.97 billion
Profitability
Miscellaneous
Employees7,600
OptionableOptionable
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories announced that its board has approved a stock buyback plan on Sunday, June 4th 2017, which allows the company to buyback 3,000,000 shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Thursday, November, 1st. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $0.97 by $0.08. The business had revenue of $545 million for the quarter, compared to the consensus estimate of $545.66 million. IDEXX Laboratories had a negative return on equity of 994.76% and a net margin of 15.19%. The company's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.76 EPS. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
How can I listen to IDEXX Laboratories' earnings call?
IDEXX Laboratories will be holding an earnings conference call on Friday, February 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8002301074.
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY19 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of $4.61-$4.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.83. The company issued revenue guidance of $2.385-$2.425 billion, compared to the consensus revenue estimate of $2.45 billion.IDEXX Laboratories also updated its FY 2017 guidance to $4.61-4.75 EPS.
What price target have analysts set for IDXX?
5 analysts have issued 1 year price targets for IDEXX Laboratories' stock. Their predictions range from $235.00 to $260.00. On average, they expect IDEXX Laboratories' share price to reach $248.00 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.
What is the consensus analysts' recommendation for IDEXX Laboratories?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.
Has IDEXX Laboratories been receiving favorable news coverage?
News articles about IDXX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IDEXX Laboratories earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Vermillion (VRML), Celldex Therapeutics (CLDX) and ImmuCell (ICCC).
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
- Mr. Jay Mazelsky, Exec. VP (Age 58)
Who are IDEXX Laboratories' major shareholders?
IDEXX Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.07%), Woodstock Corp (0.05%), Spence Asset Management (0.04%), Wendell David Associates Inc. (0.03%), Bath Savings Trust Co (0.03%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael Lane, Rebecca M Henderson and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Which major investors are selling IDEXX Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Nisa Investment Advisors LLC, Meeder Asset Management Inc., Navellier & Associates Inc, Wendell David Associates Inc., Oakbrook Investments LLC, Woodstock Corp and Louisiana State Employees Retirement System. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Michael Lane, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.
Which major investors are buying IDEXX Laboratories stock?
IDXX stock was purchased by a variety of institutional investors in the last quarter, including TrimTabs Asset Management LLC, Spence Asset Management, New England Research & Management Inc., DNB Asset Management AS, State of Alaska Department of Revenue and Ipswich Investment Management Co. Inc.. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $196.90.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $17.01 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.
What is IDEXX Laboratories' official website?
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
